New drug combo aims to wipe out stomach cancer before surgery

NCT ID NCT07483567

Recruiting now Disease control Sponsor: Innovent Biologics (Suzhou) Co. Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether adding a new drug called IBI343 to standard immunotherapy and chemotherapy can help eliminate stomach cancer more effectively before and after surgery. It involves 90 adults with a specific type of stomach cancer that has not spread widely. Participants will receive the drug combination either before and after surgery, and researchers will check how many have no cancer left after surgery.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: IBI343 (a drug targeting CLDN18.2) combined with sintilimab (an immunotherapy) and chemotherapy (oxaliplatin and S-1)
What this could lead to: If successful, this combination could improve the chance of eliminating all cancer before and after surgery for people with a specific type of gastric cancer.
What could go wrong: This is an early phase 2 trial with only 90 participants, so results may not apply to everyone. The combination may cause significant side effects, and it is not yet known if it will improve long-term survival.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CLDN18.2 POSITIVE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

gastric adenocarcinoma gastroesophageal junction adenocarcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CLDN18.2 POSITIVE GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA PRIMARY GASTRIC ADENOCARCINOMA

Contacts and locations

Locations

Beijing Cancer Hospital
RECRUITING

Beijing, Beijing Municipality, 100142, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.